

## **Global Influenza Vaccine Market Report and Forecast 2023-2031**

Market Report | 2023-05-08 | 147 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

### **Report description:**

Global Influenza Vaccine Market Report and Forecast 2023-2031

Global Influenza Vaccine Market Outlook

The global influenza vaccine market value was USD 5.9 billion in 2022, driven by the increased awareness about the health risks associated with influenza across the globe. The market size is anticipated to grow at a CAGR of 7.3% during the forecast period of 2023-2031 to achieve a value of USD 11.1 billion by 2031.

Influenza Vaccine: Introduction

Influenza vaccines, also known as flu shots, are formulated to protect against the influenza virus, a contagious respiratory illness with varying severity levels. Influenza vaccines are updated annually, as the virus mutates rapidly, and different strains circulate each flu season. The vaccines aim to stimulate an immune response by using inactivated or weakened viruses, or specific viral components like recombinant proteins or viral vectors, to mimic the natural infection.

Flu vaccines are usually trivalent or quadrivalent, meaning they protect against three or four strains of the virus, respectively. The World Health Organization (WHO) recommends the strains to be included in the vaccine each year, based on global surveillance data and predictions about the most prevalent strains for the upcoming flu season.

Influenza vaccination is recommended for most individuals, particularly those at higher risk of developing severe complications, such as the elderly, young children, pregnant women, and individuals with chronic health conditions. The vaccines are typically administered via an injection in the upper arm, but nasal spray vaccines are also available for specific age groups. While flu vaccines do not guarantee complete protection from the virus, they significantly reduce the risk of infection and minimize the severity of illness for those who contract the flu. In addition, widespread vaccination contributes to herd immunity, helping to protect vulnerable populations who may not be able to receive the vaccine themselves.

Influenza Vaccine Market Scenario

The global influenza vaccine market is witnessing significant growth as a result of increased awareness about the health risks associated with influenza and the importance of vaccination in preventing flu-related complications. Influenza, or the flu, is a highly contagious respiratory illness caused by the influenza virus, with varying degrees of severity. Annual vaccination is recommended as the virus mutates rapidly, leading to different strains circulating each flu season.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Influenza vaccines aim to stimulate an immune response using inactivated or weakened viruses or specific viral components to mimic a natural infection. These vaccines are typically trivalent or quadrivalent, meaning they protect against three or four strains of the virus, respectively. The World Health Organization (WHO) recommends the strains to be included in the vaccines each year based on global surveillance data and predictions about the most prevalent strains for the upcoming flu season.

The market's growth is driven by factors such as expanding target populations for vaccination, technological advancements in vaccine development, and increasing investments in research and development.

North America: The largest market for influenza vaccines, driven by factors such as advanced healthcare infrastructure, high vaccination rates, and significant investments in research and development.

Europe: The second-largest market, with increasing demand for flu vaccines due to a growing aging population, a supportive regulatory framework, and an expanding healthcare sector.

Asia-Pacific: Expected to witness the highest growth rate due to factors such as a rapidly growing population, increasing awareness of influenza and vaccination, and growing investments in healthcare infrastructure and research.

#### Influenza Vaccine Market Segmentations

##### Market Breakup by Vaccine Type

- Quadrivalent

- Trivalent

##### Market Breakup by Technology

- Egg Based

- Cell Based

##### Market Breakup by Age Group

- Pediatric

- Adult

##### Market Breakup by Route of Administration

- Injection

- Nasal Spray

##### Market Breakup by Distribution Channel

- Hospital Pharmacy

- Government and Institution Supply

- Others

##### Market Breakup by Region

- North America

- United States of America

- Canada

- Europe

- United Kingdom

- Germany

- France

- Italy

- Others

- Asia Pacific

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- China
- Japan
- India
- ASEAN
- Australia
- Others

- Latin America
- Brazil
- Argentina
- Mexico
- Others

- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

#### Key Trends in the Influenza Vaccine Market

Some key trends of the market are as follows:

- Increasing awareness of influenza and the importance of vaccination: The rising awareness of the health risks associated with influenza and the significance of vaccination in preventing flu-related complications has led to increased demand for flu vaccines.
- Expanding target populations for vaccination: Expanded vaccination recommendations, including wider age groups and high-risk populations, have contributed to the growth of the influenza vaccine market.
- Technological advancements in vaccine development: Innovations in vaccine development, such as cell-based and recombinant technologies, have improved the efficacy and production efficiency of influenza vaccines, further driving market growth.

#### Influenza Vaccine: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- AstraZeneca plc
- Biodiem Limited
- CSL Limited
- Emergent BioSolutions Inc.
- F. Hoffmann-La Roche AG
- Gamma Vaccines Pty Ltd
- GlaxoSmithKline Plc.
- Merck and Co., Inc.
- Pfizer Inc.
- Sanofi S.A.

#### Table of Contents:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Influenza Overview
  - 3.1 Guidelines and Stages
  - 3.2 Pathophysiology
  - 3.3 Screening and Diagnosis
  - 3.4 Treatment Pathway
- 4 Patient Profile
  - 4.1 Patient Profile Overview
  - 4.2 Patient Psychology and Emotional Impact Factors
  - 4.3 Risk Assessment and Treatment Success Rate
- 5 Influenza Epidemiology Analysis
  - 5.1 Epidemiology Overview (2016-2031)
  - 5.2 North America Influenza Epidemiology (2016-2031)
  - 5.3 Europe Influenza Epidemiology (2016-2031)
  - 5.4 Asia-Pacific Influenza Epidemiology (2016-2031)
  - 5.5 Latin America Influenza Epidemiology (2016-2031)
  - 5.6 Middle East & Africa Influenza Epidemiology (2016-2031)
- 6 Global Influenza Vaccine Market Overview
  - 6.1 Global Influenza Vaccine Market Historical Value (2016-2022)
  - 6.2 Global Influenza Vaccine Market Forecast Value (2023-2031)
- 7 Global Influenza Vaccine Market Landscape
  - 7.1 Global Influenza Vaccine Developers Landscape
    - 7.1.1 Analysis by Year of Establishment
    - 7.1.2 Analysis by Company Size
    - 7.1.3 Analysis by Region
  - 7.2 Global Influenza Vaccine Product Landscape
    - 7.2.1 Analysis by Vaccine Type
    - 7.2.2 Analysis by Technology
    - 7.2.3 Analysis by Age Group
- 8 Influenza Vaccine Challenges and Unmet Needs
  - 8.1 Treatment Pathway Challenges
  - 8.2 Compliance and Drop-Out Analysis
  - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Global Influenza Vaccine Market Dynamics
  - 10.1 Market Drivers and Constraints
  - 10.2 SWOT Analysis
  - 10.3 Porter's Five Forces Model
  - 10.4 Key Demand Indicators
  - 10.5 Key Price Indicators
  - 10.6 Industry Events, Initiatives, and Trends
  - 10.7 Value Chain Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11 Global Influenza Vaccine Market Segmentation
  - 11.1 Global Influenza Vaccine Market by Vaccine Type
    - 11.1.1 Market Overview
    - 11.1.2 Quadrivalent
    - 11.1.3 Trivalent
  - 11.2 Global Influenza Vaccine Market by Technology
    - 11.2.1 Market Overview
    - 11.2.2 Egg Based
    - 11.2.3 Cell Based
  - 11.3 Global Influenza Vaccine Market by Age Group
    - 11.3.1 Market Overview
    - 11.3.2 Pediatric
    - 11.3.3 Adult
  - 11.4 Global Influenza Vaccine Market by Route of Administration
    - 11.4.1 Market Overview
    - 11.4.2 Injection
    - 11.4.3 Nasal Spray
  - 11.5 Global Influenza Vaccine Market by Distribution Channel
    - 11.5.1 Market Overview
    - 11.5.2 Hospital Pharmacy
    - 11.5.3 Government and Institution Supply
    - 11.5.4 Others
  - 11.6 Global Influenza Vaccine Market by Region
    - 11.6.1 Market Overview
    - 11.6.2 North America
    - 11.6.3 Europe
    - 11.6.4 Asia Pacific
    - 11.6.5 Latin America
    - 11.6.6 Middle East and Africa
- 12 North America Influenza Vaccine Market
  - 12.1 Market Share by Country
  - 12.2 United States of America
  - 12.3 Canada
- 13 Europe Influenza Vaccine Market
  - 13.1 Market Share by Country
  - 13.2 United Kingdom
  - 13.3 Germany
  - 13.4 France
  - 13.5 Italy
  - 13.6 Others
- 14 Asia Pacific Influenza Vaccine Market
  - 14.1 Market Share by Country
  - 14.2 China
  - 14.3 Japan
  - 14.4 India
  - 14.5 ASEAN
  - 14.6 Australia

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 14.7 Others
- 15 Latin America Influenza Vaccine Market
  - 15.1 Market Share by Country
  - 15.2 Brazil
  - 15.3 Argentina
  - 15.4 Mexico
  - 15.5 Others
- 16 Middle East and Africa Influenza Vaccine Market
  - 16.1 Market Share by Country
  - 16.2 Saudi Arabia
  - 16.3 United Arab Emirates
  - 16.4 Nigeria
  - 16.5 South Africa
  - 16.6 Others
- 17 Patent Analysis
  - 17.1 Analysis by Type of Patent
  - 17.2 Analysis by Publication year
  - 17.3 Analysis by Issuing Authority
  - 17.4 Analysis by Patent Age
  - 17.5 Analysis by CPC Analysis
  - 17.6 Analysis by Patent Valuation
  - 17.7 Analysis by Key Players
- 18 Grants Analysis
  - 18.1 Analysis by year
  - 18.2 Analysis by Amount Awarded
  - 18.3 Analysis by Issuing Authority
  - 18.4 Analysis by Grant Application
  - 18.5 Analysis by Funding Institute
  - 18.6 Analysis by NIH Departments
  - 18.7 Analysis by Recipient Organization
- 19 Clinical Trials Analysis
  - 19.1 Analysis by Trial Registration Year
  - 19.2 Analysis by Trial Status
  - 19.3 Analysis by Trial Phase
  - 19.4 Analysis by Therapeutic Area
  - 19.5 Analysis by Geography
- 20 Funding Analysis
  - 20.1 Analysis by Funding Instances
  - 20.2 Analysis by Type of Funding
  - 20.3 Analysis by Funding Amount
  - 20.4 Analysis by Leading Players
  - 20.5 Analysis by Leading Investors
  - 20.6 Analysis by Geography
- 21 Partnership and Collaborations Analysis
  - 21.1 Analysis by Partnership Instances
  - 21.2 Analysis by Type of Partnership
  - 21.3 Analysis by Leading Players

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 21.4 Analysis by Geography
- 22 Regulatory Framework
  - 22.1 Regulatory Overview
    - 22.1.1 US FDA
    - 22.1.2 EU EMA
    - 22.1.3 INDIA CDSCO
    - 22.1.4 JAPAN PMDA
    - 22.1.5 Others
- 23 Supplier Landscape
  - 23.1 AstraZeneca plc
    - 23.1.1 Financial Analysis
    - 23.1.2 Product Portfolio
    - 23.1.3 Demographic Reach and Achievements
    - 23.1.4 Mergers and Acquisitions
    - 23.1.5 Certifications
  - 23.2 Biodiem Limited
    - 23.2.1 Financial Analysis
    - 23.2.2 Product Portfolio
    - 23.2.3 Demographic Reach and Achievements
    - 23.2.4 Mergers and Acquisitions
    - 23.2.5 Certifications
  - 23.3 CSL Limited
    - 23.3.1 Financial Analysis
    - 23.3.2 Product Portfolio
    - 23.3.3 Demographic Reach and Achievements
    - 23.3.4 Mergers and Acquisitions
    - 23.3.5 Certifications
  - 23.4 Emergent BioSolutions Inc.
    - 23.4.1 Financial Analysis
    - 23.4.2 Product Portfolio
    - 23.4.3 Demographic Reach and Achievements
    - 23.4.4 Mergers and Acquisitions
    - 23.4.5 Certifications
  - 23.5 F. Hoffmann-La Roche AG
    - 23.5.1 Financial Analysis
    - 23.5.2 Product Portfolio
    - 23.5.3 Demographic Reach and Achievements
    - 23.5.4 Mergers and Acquisitions
    - 23.5.5 Certifications
  - 23.6 Gamma Vaccines Pty Ltd
    - 23.6.1 Financial Analysis
    - 23.6.2 Product Portfolio
    - 23.6.3 Demographic Reach and Achievements
    - 23.6.4 Mergers and Acquisitions
    - 23.6.5 Certifications
  - 23.7 GlaxoSmithKline Plc.
    - 23.7.1 Financial Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Mergers and Acquisitions
- 23.7.5 Certifications
- 23.8 Merck and Co., Inc.
  - 23.8.1 Financial Analysis
  - 23.8.2 Product Portfolio
  - 23.8.3 Demographic Reach and Achievements
  - 23.8.4 Mergers and Acquisitions
  - 23.8.5 Certifications
- 23.9 Pfizer Inc.
  - 23.9.1 Financial Analysis
  - 23.9.2 Product Portfolio
  - 23.9.3 Demographic Reach and Achievements
  - 23.9.4 Mergers and Acquisitions
  - 23.9.5 Certifications
- 23.10 Sanofi S.A.
  - 23.10.1 Financial Analysis
  - 23.10.2 Product Portfolio
  - 23.10.3 Demographic Reach and Achievements
  - 23.10.4 Mergers and Acquisitions
  - 23.10.5 Certifications
- 23.11 Others
- 24 Global Influenza Vaccine Market- Distribution Model (Additional Insight)
  - 24.1 Overview
  - 24.2 Potential Distributors
  - 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Company Competitiveness Analysis (Additional Insight)
  - 26.1 Very Small Companies
  - 26.2 Small Companies
  - 26.3 Mid-Sized Companies
  - 26.4 Large Companies
  - 26.5 Very Large Companies
- 27 Payment Methods (Additional Insight)
  - 27.1 Government Funded
  - 27.2 Private Insurance
  - 27.3 Out-of-Pocket

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Global Influenza Vaccine Market Report and Forecast 2023-2031**

Market Report | 2023-05-08 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com